Insys Therapeutics (NASDAQ:INSY) : Traders are bullish on Insys Therapeutics (NASDAQ:INSY) as it has outperformed the S&P 500 by a wide margin of 10.16% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 14.79%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 16.26% in the last 1 week, and is up 11.94% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The company shares have dropped -59.08% from its 1 Year high price. On Aug 5, 2015, the shares registered one year high at $46.17 and the one year low was seen on Jun 27, 2016. The 50-Day Moving Average price is $14.45 and the 200 Day Moving Average price is recorded at $17.27.
The stock has recorded a 20-day Moving Average of 16.83% and the 50-Day Moving Average is 10.73%.
Insys Therapeutics (NASDAQ:INSY): stock turned positive on Friday. Though the stock opened at $15.41, the bulls momentum made the stock top out at $16 level for the day. The stock recorded a low of $15.25 and closed the trading day at $15.66, in the green by 2.15%. The total traded volume for the day was 732,805. The stock had closed at $15.33 in the previous days trading.
In an insider trading activity,The director of Insys Therapeutics, Inc., Stanley Theodore H sold 16,000 shares at $16.27 on June 6, 2016. The Insider selling transaction had a total value worth of $260,320. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company has two marketed products: Subsys, a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and Dronabinol SG Capsule, a generic equivalent to Marinol (dronabinol), an approved second-line treatment of chemotherapy-induced nausea and vomiting (CINV), and anorexia associated with weight loss in patients with AIDS. The Companys lead product candidate is Dronabinol oral solution, an orally administered liquid formulation of dronabinol. Dronabinol oral solution has demonstrated more rapidly detectable blood levels and a more reliable absorption profile than Marinol in its clinical studies.